Identification of Small Molecule Enhancers of Immunotherapy for Melanoma.

ABSTRACT: Small molecule based targeted therapies for the treatment of metastatic melanoma hold promise but responses are often not durable, and tumors frequently relapse. Response to adoptive cell transfer (ACT)-based immunotherapy in melanoma patients are durable but patients develop resistance primarily due to loss of antigen expression. The combination of small molecules that sustain T cell effector function with ACT could lead to long lasting responses. Here, we have developed a novel co-culture cell-based high throughput assay system to identify compounds that could potentially synergize or enhance ACT-based immunotherapy of melanoma. A BRAF^V600E mutant melanoma cell line, SB-3123_p which is resistant to Pmel-1-directed ACT due to low gp100 expression levels was used to de

SUBMITTER: Dextras C 

PROVIDER: S-EPMC7105471 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature